181 related articles for article (PubMed ID: 20108746)
1. Intraprostatic botulinum toxin injection in patients with benign prostatic enlargement.
Ilie CP; Chancellor MB; Chuang YC; Dan M
J Med Life; 2009; 2(4):338-42. PubMed ID: 20108746
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
3. [Effects of intraprostatic injection of botulinum toxin A (BTX-A) on benign prostate hyperplasia].
Xu YP; Yu X; Ye ZQ; Pan TJ; Wen HD; Wang T
Zhonghua Nan Ke Xue; 2010 Oct; 16(10):905-10. PubMed ID: 21243754
[TBL] [Abstract][Full Text] [Related]
4. [What role does botulinum toxin play in the treatment of benign prostatic hyperplasia?].
Mazdar A; Bedouche A; Zoughari S; Ibrahimi A; Sayegh HE; Iken A; Benslimane L; Nouini Y
Pan Afr Med J; 2016; 24():309. PubMed ID: 28154664
[TBL] [Abstract][Full Text] [Related]
5. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
[TBL] [Abstract][Full Text] [Related]
6. Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs.
Chuang YC; Tu CH; Huang CC; Lin HJ; Chiang PH; Yoshimura N; Chancellor MB
BMC Urol; 2006 Apr; 6():12. PubMed ID: 16620393
[TBL] [Abstract][Full Text] [Related]
7. [Preliminary results of botulinum toxin in the treatment of benign prostatic hyperplasia].
Caremel R; Albouy B; De Fourmestraux A; Tanneau Y; Grise P
Prog Urol; 2007 Jun; 17(4):796-800. PubMed ID: 17633989
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Benign Prostatic Hyperplasia by Ultrasound-Guided Botulinum Toxin Type A Injection.
Ding XD; Chen HX; Xiao HQ; Wang W; Ding ZG; Zhang GB; Fu DG
Cell Biochem Biophys; 2015 Nov; 73(2):357-359. PubMed ID: 27352323
[TBL] [Abstract][Full Text] [Related]
9. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia.
Chuang YC; Chiang PH; Yoshimura N; De Miguel F; Chancellor MB
BJU Int; 2006 Nov; 98(5):1033-7; discussion 1337. PubMed ID: 16956361
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Botulinum Toxin-A intraprostatic injection for benign prostatic hyperplasia induced lower urinary tract symptoms: A prospective multicenter study.
Moussa AS; Ragheb AM; Abdelbary AM; Ibrahim RM; El Adawy MS; Aref A; Assem A; Elfayoumy H; Elzawy F
Prostate; 2019 Aug; 79(11):1221-1225. PubMed ID: 31189024
[TBL] [Abstract][Full Text] [Related]
11. Perspective of Botox for treatment of male lower urinary tract symptoms.
Ilie CP; Chancellor MB
Curr Opin Urol; 2009 Jan; 19(1):20-5. PubMed ID: 19057212
[TBL] [Abstract][Full Text] [Related]
12. The use of botulinum toxin for treatment of lower urinary tract symptoms.
Lucioni A; Reynolds WS; Rapp DE; Katz M; Bales GT
Minerva Urol Nefrol; 2008 Jun; 60(2):93-103. PubMed ID: 18500224
[TBL] [Abstract][Full Text] [Related]
13. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.
Maria G; Brisinda G; Civello IM; Bentivoglio AR; Sganga G; Albanese A
Urology; 2003 Aug; 62(2):259-64; discussion 264-5. PubMed ID: 12893330
[TBL] [Abstract][Full Text] [Related]
14. Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality.
Hsu YC; Wang HJ; Chuang YC
Toxins (Basel); 2016 Apr; 8(5):. PubMed ID: 27128942
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Wang F; Palacios JM; Vasylyev A; Manyak MJ
BJU Int; 2015 Sep; 116(3):450-9. PubMed ID: 25565364
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis.
Shim SR; Cho YJ; Shin IS; Kim JH
Int Urol Nephrol; 2016 Jan; 48(1):19-30. PubMed ID: 26560471
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat.
Silva J; Pinto R; Carvallho T; Coelho A; Avelino A; Dinis P; Cruz F
Eur Urol; 2009 Jul; 56(1):134-40. PubMed ID: 18649990
[TBL] [Abstract][Full Text] [Related]
18. Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia: preliminary results with a newly purified neurotoxin.
Yokoyama T; Yamamoto Y; Suzuki T; Oguma K; Nagai A
Acta Med Okayama; 2012; 66(4):291-7. PubMed ID: 22918201
[TBL] [Abstract][Full Text] [Related]
19. [Benign prostatic hyperplasia--botulinum toxin A in BPH with small prostate volume].
Adler S
Aktuelle Urol; 2006 Sep; 37(5):315-6; discussion 315-6. PubMed ID: 17004177
[No Abstract] [Full Text] [Related]
20. The application of botulinum toxin in the prostate.
Chuang YC; Chancellor MB
J Urol; 2006 Dec; 176(6 Pt 1):2375-82. PubMed ID: 17085104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
